Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.verified

MDGL

Price:

$229.58

Market Cap:

$4.89B

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.[Read more]

Industry

Biotechnology

IPO Date

2007-02-06

Stock Exchange

NASDAQ

Ticker

MDGL

The PE Ratio as of May 2024 (TTM) for Madrigal Pharmaceuticals, Inc. (MDGL) is -9.93

According to Madrigal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.93. This represents a change of 4.49% compared to the average of -9.50 of the last 4 quarters.

Madrigal Pharmaceuticals, Inc. (MDGL) Historical PE Ratio (quarterly & annually)

How has MDGL PE Ratio performed in the past?

The mean historical PE Ratio of Madrigal Pharmaceuticals, Inc. over the last ten years is -15.49. The current -9.93 PE Ratio has changed 6.31% with respect to the historical average. Over the past ten years (40 quarters), MDGL's PE Ratio was at its highest in in the March 2016 quarter at -0.06. The PE Ratio was at its lowest in in the June 2018 quarter at -155.69.

Quarterly (TTM)
Annual

Average

-15.49

Median

-10.14

Minimum

-50.83

Maximum

-0.03

Madrigal Pharmaceuticals, Inc. (MDGL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Madrigal Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 9.53%

Maximum Annual PE Ratio = -0.03

Minimum Annual Increase = -98.99%

Minimum Annual PE Ratio = -50.83

Quarterly (TTM)
Annual
YearPE RatioChange
2023-11.57-30.36%
2022-16.62185.92%
2021-5.81-33.17%
2020-8.70-54.85%
2019-19.26-62.10%
2018-50.8340.90%
2017-36.081.13%
2016-2.949.53%
2015-0.03-98.99%
2014-3.03-26.54%

Madrigal Pharmaceuticals, Inc. (MDGL) Average PE Ratio

How has MDGL PE Ratio performed in the past?

The current PE Ratio of Madrigal Pharmaceuticals, Inc. (MDGL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-11.33

5-year avg

-12.39

10-year avg

-15.49

Madrigal Pharmaceuticals, Inc. (MDGL) PE Ratio vs. Peers

How is MDGL’s PE Ratio compared to its peers?

Madrigal Pharmaceuticals, Inc.’s PE Ratio is greater than Intercept Pharmaceuticals, Inc. (-13.55), less than TG Therapeutics, Inc. (59.30), less than Terns Pharmaceuticals, Inc. (-4.90), less than Hepion Pharmaceuticals, Inc. (-0.15), greater than Viking Therapeutics, Inc. (-69.27), less than Sarepta Therapeutics, Inc. (686.76), less than PTC Therapeutics, Inc. (-4.91), less than Day One Biopharmaceuticals, Inc. (-5.71), less than X4 Pharmaceuticals, Inc. (-1.40), less than Inozyme Pharma, Inc. (-3.66), less than Acumen Pharmaceuticals, Inc. (-3.64), greater than Mereo BioPharma Group plc (-58.75), less than 89bio, Inc. (-4.73), less than Pliant Therapeutics, Inc. (-4.49), greater than Arcellx, Inc. (-54.17), less than Stoke Therapeutics, Inc. (-6.14), less than Krystal Biotech, Inc. (80.60), less than Iovance Biotherapeutics, Inc. (-5.93),

Build a custom stock screener for Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Madrigal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Madrigal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Madrigal Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Madrigal Pharmaceuticals, Inc. (MDGL)?

What is the highest PE Ratio for Madrigal Pharmaceuticals, Inc. (MDGL)?

What is the 3-year average PE Ratio for Madrigal Pharmaceuticals, Inc. (MDGL)?

What is the 5-year average PE Ratio for Madrigal Pharmaceuticals, Inc. (MDGL)?

How does the current PE Ratio for Madrigal Pharmaceuticals, Inc. (MDGL) compare to its historical average?